Abstract 49P
Background
There is scant data on outcomes of HER2-positive breast cancer patients treated with neoadjuvant therapy in real-world, resource-constrained settings. Factors affecting outcomes in patients who achieve pathological complete response (pCR) are insufficiently explored.
Methods
This was a retrospective analysis of HER2-positive breast cancer patients treated with neoadjuvant chemotherapy (NACT) with or without HER2-targeted therapy between Jan 2014 & Dec 2018. The endpoints were pCR, event-free survival (EFS) and overall survival (OS).
Results
1004 patients were included in the analysis with a median age of 47 years, 533 (53.1%) with cT3/T4, 466 (46.4%) with cN2/3, 527 (52.5%) with ER/PR-positive tumours, 528 (52.3%) received HER2-therapy with NACT, and 711 (70.8%) received it anytime during curative treatment. The 5-year EFS in all patients was 63.5% (95%CI 60.36-66.63%) and was significantly higher with pCR vs without pCR (86.1% vs 57.0%, HR 0.282, 95%CI 0.198-0.401, p=0.000), cT1/T2 vs cT3/T4 (66.8% vs 60.6%, HR 0.767, 95%CI 0.626-0.939, p=0.01), cN0/N1 vs cN2/N3 (67.9% vs 58.5%, HR 0.772, 95%CI 0.632-0.944, p=0.01), and ever-received vs never-received HER2-therapy (69.5% vs 50.1%, HR 0.537, 95%CI 0.438-0.659, p=0.000). The 5-year OS in all patients was 69.6% (95%CI 66.66-72.54%) and was significantly higher in pCR, cT1/T2, cN0/N1, and ever-received HER2-therapy subgroups. In the pCR subgroup (n=226), there was a trend towards higher 5-year EFS among patients with cT1/T2 vs cT3/T4 (90.0% vs 82.5%, HR 0.546, 95%CI 0.270-1.103, p=0.08), cN0/N1 vs cN2/N3 (89.3% vs 82.4%, HR 0.641, 95%CI 0.326-1.262, p=0.195), and ER/PR-positive) vs ER/PR-negative tumours (90.9% vs 83.0%, HR 0.609, 95%CI 0.291-1.274, p=0.183), but there was no difference between ever-received (n=204) vs never-received (n=22) HER2-therapy (86.1% vs 86.4%, HR 0.880, 95%CI 0.309-2.504, p=0.811).
Conclusions
The receipt of HER2-targeted therapy and achievement of pCR significantly impact survival of HER2-positive breast cancer patients treated with neoadjuvant therapy. In patients who achieve pCR baseline disease burden tends to influence survival but not receipt of HER2-targeted therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract
101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Presenter: Kota Ouchi
Session: Poster Display
Resources:
Abstract